iBio, Inc. (IBIO) Stock Score, Valuation & Financial Research

iBio, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 22/100.

Quick answer for IBIO

iBio, Inc. currently has a Wall Street Score of 22/100. The stored market price is USD 1.18. Its financial score is 25/100. Its valuation score is 0/100. The latest WSS change is +5.7 points. These figures are a research snapshot, not a buy or sell recommendation.

What iBio, Inc. does

iBio, Inc., a United States-based biotechnology firm, delivers contract development and manufacturing (CDMO) services to its collaborators and external clients. Its operations are structured into two distinct segments: Biopharmaceuticals and Bioprocessing. The company's leading therapeutic candidate, IBIO-100, is currently progressing through investigational new drug (IND) development, aimed at addressing systemic scleroderma and idiopathic pulmonary fibrosis. Additionally, iBio is engaged in the preclinical development of vaccine candidates, including IBIO-200 and IBIO-201, designed to prevent severe acute respiratory syndrome coronavirus 2. Another candidate, IBIO-400, is in development for the treatment of classical swine fever. Beyond its proprietary pipeline, iBio provides recombinant proteins to third parties, available both as catalog items and custom-synthesized products. It also offers comprehensive services spanning process development, advanced manufacturing, filling and finishing, and bioanalytical support. iBio maintains several strategic partnerships: a licensing agreement with Planet Biotechnology, Inc. for infectious disease therapeutics; a collaborative effort with The Texas A&M University System focused on COVID-19 vaccine candidates; a licensing pact with the University of Natural Resources and Life Sciences, Vienna; and a collaboration with CC-Pharming Ltd. Its corporate headquarters are situated in Bryan, Texas.

Company business and revenue

Research reporting period: 2026-06-30. A research update is not a new financial filing.

How the company makes money

iBio is a clinical-stage biotechnology company that leverages an AI-driven drug discovery platform to develop proprietary antibody therapeutics. The company focuses on addressing unmet medical needs in obesity, cardiometabolic, and cardiopulmonary diseases through the research and development of novel biologics.

Products and services

  • The company's primary product candidate is IBIO-600, a long-acting anti-myostatin monoclonal antibody currently in Phase 1 clinical development for obesity and related conditions.

Annual revenue by business

  • Collaborative Revenues: USD 100,000 · 100.00% calculated revenue share (period 2026-06-30) Source

Revenue share is not a unit-sales or best-seller ranking. Categories may overlap; do not add rows from different breakdowns.

Customer types

Pharmaceutical and biotechnology companies.

Business strengths to evaluate

  • Proprietary AI Drug Discovery Platform Source
  • Clinical-stage pipeline focused on high-growth obesity and cardiometabolic markets Source

Business risks and research considerations

  • History of operating losses and potential need for additional capital Source
  • Risks associated with clinical trial success, regulatory approval, and commercialization Source

Sources: Company research source · Collaborative Revenues

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

Financial risk observations and what to check

These are saved observations about business performance, not predictions. Review the company filings alongside the interpretation below. Latest stored financial period end: 2026-06-30.

  • Quarterly revenue fell 100.0% versus the same quarter last year. Check comparable business scope and currency, then separate volume, pricing and divestitures. One weaker quarter does not establish that the same decline will continue.
  • Diluted weighted-average shares increased 533.6% year over year. Compare per-share results with total earnings and inspect the equity footnote. A change in weighted-average shares does not by itself establish the cause, the number of shares issued today, or the economic effect of a split.

IBIO financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
22/100
Stored price:
USD 1.18
Market capitalization:
75.88M (currency not supplied)
Revenue:
USD 100K
Net income:
USD -33.04M
Free cash flow:
USD -23.8M
Cash:
USD 56.4M
Total debt:
USD 2.2M
EPS:
USD -0.33
Financial score:
25/100
Valuation score:
0/100
Revenue score:
0/100

What stands out

  • Reported year-over-year revenue growth is +0.0%.
  • Free cash flow is USD -23.8M, negative for the stored period.
  • The balance sheet shows USD 56.4M of cash versus USD 2.2M of total debt, an excess of cash over debt on these two reported measures.
  • The latest Wall Street Score change is +5.7 points: IBIO increased 5.7 points because Asset improved by 41.3 points.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 54.2M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for IBIO

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • Can IBIO maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
  • How long can IBIO fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is IBIO likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for IBIO to reach sustainable profitability?
  • What future growth or profitability would be needed to justify IBIO's current valuation?

What the numbers mean

Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.

The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 100% of the scoring inputs required for this public page are currently available.

How to research IBIO

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.